Skip to main content
OpenTrials
Completed

NCT Number: NCT06211829

An Evaluation of a Antimicrobial Stewardship Recommendation Bundle for Staphylococcus Aureus Bloodstream Infections

In July 2020, a bundle (Appendix C) was implemented at Methodist Dallas Medical Center where all patients with SAB were reviewed by the antimicrobial stewardship pharmacist (Monday - Friday from 0700 to 1500), a note outlining optimal interventions was written in the electronic medical record (EMR), and the recommendations were communicated to the primary team via secure messaging or telephone

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bacterial Infections Bacterial Infections and Mycoses Infections

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Methodist Dallas Medical Center

Dallas, Texas, 75203, United States

About this study

Evaluation of the Staphylococcus aureus bloodstream infection(SAB)bundle recommendations will allow for determination of whether this intervention is impactful and warrants the resources currently devoted to it.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age SAB during hospital admission

Exclusion criteria

  • Patients with a history of a prior SAB during the study period (only first occurrence included)
  • Blood culture collected within 48hours of patient expiring or transitioning to hospice
  • Patients discharged or left before culture results were available
  • Patients transferred from an outside hospital

Treatment and study plan

Primary outcomes

  1. number of Staphylococcus Aureus blood stream infections (SAB)

    Time frame: 12 weeks

    Number of SAB occurring

Secondary outcomes

  1. Number of In-hospital mortality

    Time frame: 12 weeks

    Number of In-hospital mortality

  2. number of times of bacteremia

    Time frame: 12 weeks

    time of bacteremia

  3. number of days of stay

    Time frame: 12 weeks

    duration of hospital stay

  4. number of times of readmission

    Time frame: 12 weeks

    Number time of readmission

  5. number of infection

    Time frame: 12 weeks

    Number of times the infection is occurring

Sponsors and collaborators

Lead sponsor

Methodist Health System

Other

Registry information

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Jan 18, 2024
Registry last updated
Aug 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.